Compare Moderna, Inc. (MRNA) vs State Street Technology Select Sector SPDR ETF (XLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs State Street Technology Select Sector SPDR ETF — how do they compare? Moderna, Inc. trades at $63.7 (market cap $24.18B), while State Street Technology Select Sector SPDR ETF trades at $188.99. The key difference: State Street Technology Select Sector SPDR ETF is trading nearer its 52-week high, Moderna, Inc. nearer its low. Which is the better fit depends on your goals.
| MRNA | XLK | |
|---|---|---|
Market Cap | $24.18B | — |
Sector | Health | Sector/Thematic |
52-Week High | $81.80 | $198.21 |
52-Week Low | $22.36 | $127.49 |
Enterprise Value | $20.33B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
XLK trades at $188.86, up 1.36% with a bullish technical signal from moving averages. The ETF shows strong momentum near resistance at $189, supported by sector inflows and earnings growth. Recent news highlights tech sector leadership and investor accumulation during selloffs, though concentration risk remains a concern.
Outlook is positive with tech earnings driving gains, but overbought RSI and high dependence on mega-caps pose near-term risks. Long-term growth hinges on AI adoption and sector diversification, with analysts favoring broad tech exposure alternatives for valuation advantages.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About State Street Technology Select Sector SPDR ETF
XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →
